Evidence map›Paper›PMID 31619071›Full record

ArticleJournal of diabetes science and technology2021

Five-Month Follow-up Shows No Improvement in Dermatological Complications in Children With Type 1 Diabetes Using Continuous Glucose Monitoring Systems and Insulin Pumps.

Anna T Weng, Claus Zachariae, Karl B Christensen, Jannet Svensson, Anna K Berg

Open access · bronzeAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Barriers to Type 1 Diabetes Adherence in Adolescents.Journal of clinical medicine · 2024
    Review
  4. Diabetes Technology Meeting 2021.Journal of diabetes science and technology · 2022
    Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Anna T WengDepartment of Pediatrics, Copenhagen University Hospital, Herlev Hospital, Denmark.ORCID 0000-0002-9903-1901
Claus ZachariaeDepartment of Dermatology and Allergy, Copenhagen University Hospital, Gentofte Hospital, Denmark.
Karl B ChristensenDepartment of Public Health, Section of Biostatistics, University of Copenhagen, Denmark.
Jannet SvenssonDepartment of Pediatrics, Copenhagen University Hospital, Herlev Hospital, Denmark.
Anna K BergDepartment of Pediatrics, Copenhagen University Hospital, Herlev Hospital, Denmark.
University of Copenhagen · DKGentofte Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA Danish study showed that 90% of the pediatric patients who participated had some time experienced dermatological complications due to treatment with continuous subcutaneous insulin infusion (CSII). This follow-up study describes dermatological complications due to CSII and/or continuous glucose monitoring (CGM) between the two study periods and includes health-related quality of life (HrQoL) measurements.

methodsA total of 138 patients (95%) out of 145 patients from the initial study answered an online questionnaire regarding dermatological complications related to CSII and/or CGM, five months later. A second questionnaire (DISABKIDS) regarding HrQoL was sent out to those 138 of which 111 patients completed it. The patients were aged from 2 to 20 years. Descriptive statistics, χ

resultsIn total, 81% of the 138 patients continued to have dermatological complications at follow-up. Itching was the most frequently reported complication. Patients using Enlite reported more dermatological complications than those using Libre. In total, 79% of the patients who used barrier cream in the initial study still had dermatological complications five months later. Age, gender, Body Mass Index (BMI), or HbA1c levels showed no significant association with dermatological complications. Patients who perceived dermatological complications as a greater problem had lower HrQoL scores.

conclusionOnce dermatological complications start to appear, they become chronic, indicating that the treatments currently available are inadequate. Patients perceiving dermatological complications as a greater problem were associated with lower HrQoL. These findings highlight the need for additional preventive studies.

Indexed as

Diabetes Mellitus, Type 1Blood GlucoseBlood Glucose Self-MonitoringChildFollow-Up StudiesHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsQuality of LifeBlood GlucoseHypoglycemic AgentsInsulinCGMchildrenCSIIdermatological complicationsquality of lifetype 1 diabetes

Identifiers

PMID31619071
PMCPMC8256062
OpenAlexW2981067726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.